Skip to main content
. 2020 Sep 17;11(1):984–1000. doi: 10.1080/21655979.2020.1814683

Table 5.

Summary of the MAM monitoring of the modified peptides.

H-chain/
L-chain		 Peptide name Relative peak area percentage
 Total average CVb Modification (site)
Day 1
 Day 2
 Day 3
1 2 3 Average CVa 1 2 3 Average CVa 1 2 3 Average CVa
H-chain TTHd-1 1.83 1.80 1.83 1.82 0.82 1.80 1.86 1.92 1.86 3.35 1.81 1.80 1.81 1.80 0.46 1.83 2.20 Pyroglutamination (E1)
TTH-5 0.97 1.00 0.96 0.97 1.99 0.97 0.97 0.97 0.97 0.39 0.88 0.86 0.86 0.87 1.10 0.94 5.85 Deamidation (N55)
TTH-8 2.99 2.83 2.51 2.78 8.93 4.03 3.87 3.97 3.96 2.03 2.12 2.28 2.44 2.28 7.08 3.01 25.33 Oxidation (M83)
THe-16 7.33 6.93 6.34 6.87 7.23 8.63 8.50 8.50 8.55 0.87 5.67 6.04 6.26 5.99 4.93 7.13 16.29 Oxidation (M255)
TH-19 39.43 39.28 39.42 39.38 0.21 39.43 39.64 39.50 39.52 0.27 39.59 39.43 39.43 39.48 0.24 39.46 0.26 A2G0Fc (N300)
TH-19 33.00 32.76 32.70 32.82 0.49 32.99 32.85 33.10 32.98 0.39 32.76 32.82 32.88 32.82 0.17 32.87 0.41 A2G1Fc (N300)
TH-19 7.22 7.48 7.45 7.38 1.97 7.16 7.31 7.17 7.22 1.19 7.27 7.28 7.24 7.27 0.27 7.29 1.56 A1G0Fc (N300)
TH-19 5.02 4.94 4.97 4.98 0.82 4.98 5.10 4.97 5.02 1.48 5.01 5.07 5.07 5.05 0.72 5.01 1.12 A2G2Fc (N300)
TH-19 4.30 4.34 4.28 4.31 0.66 4.33 4.24 4.31 4.29 1.13 4.37 4.38 4.33 4.36 0.57 4.32 1.01 A2G0c (N300)
TH-19 2.35 2.42 2.41 2.40 1.73 2.35 2.37 2.27 2.33 2.29 2.34 2.33 2.36 2.34 0.65 2.36 1.95 A1G1Fc (N300)
TH-19 2.27 2.24 2.24 2.25 0.86 2.23 2.18 2.19 2.20 1.33 2.19 2.21 2.19 2.20 0.62 2.22 1.43 M5c (N300)
TH-19 1.80 1.78 1.75 1.78 1.21 1.74 1.75 1.78 1.76 1.27 1.81 1.79 1.78 1.79 0.81 1.78 1.34 A2G1c (N300)
TH-19 1.47 1.49 1.50 1.49 0.89 1.50 1.42 1.47 1.47 2.75 1.46 1.47 1.52 1.48 2.24 1.48 1.93 A1G0c (N300)
TH-19 0.58 0.59 0.60 0.59 2.22 0.62 0.57 0.59 0.60 3.67 0.58 0.59 0.58 0.58 0.88 0.59 2.38 A2S1G1Fc (N300)
TH-19 0.42 0.43 0.44 0.43 1.52 0.45 0.43 0.44 0.44 2.36 0.44 0.42 0.43 0.43 2.04 0.43 1.89 A2S1G0Fc (N300)
TH-19 0.34 0.35 0.34 0.35 1.55 0.33 0.32 0.34 0.33 3.80 0.34 0.34 0.34 0.34 0.19 0.34 2.92 A1G1c (N300)
TH-19 0.20 0.21 0.20 0.20 2.45 0.21 0.20 0.20 0.21 3.17 0.20 0.21 0.20 0.20 1.16 0.20 2.24 A1S1Fc (N300)
TH-19 0.16 0.19 0.20 0.18 10.54 0.20 0.20 0.20 0.20 0.83 0.19 0.20 0.19 0.19 2.50 0.19 6.21 A2S2Fc (N300)
TH-19 0.16 0.18 0.17 0.17 5.08 0.17 0.15 0.17 0.16 5.99 0.16 0.15 0.17 0.16 4.86 0.16 5.06 A2G2c (N300)
TH-19 0.13 0.12 0.12 0.12 3.64 0.13 0.13 0.13 0.13 1.68 0.12 0.13 0.13 0.13 2.08 0.13 3.53 M6c (N300)
TH-19 0.11 0.11 0.11 0.11 0.69 0.11 0.10 0.10 0.11 2.06 0.10 0.10 0.10 0.10 0.99 0.10 2.95 A1G1M5c (N300)
TH-22 4.23 4.12 3.82 4.06 5.27 5.11 5.44 5.39 5.31 3.36 3.18 3.31 3.50 3.33 4.73 4.23 20.88 Oxidation (M361)
TH-28 98.66 98.68 98.74 98.69 0.04 98.71 98.71 98.74 98.72 0.02 98.74 98.74 98.74 98.74 <0.01 98.72 0.03 C-terminal Lys clipping (G449)
L-chain TTLd-1 3.84 4.09 3.63 3.85 5.98 6.09 6.43 6.20 6.24 2.77 2.87 3.16 3.01 3.01 4.89 4.37 33.36 Oxidation (M4)
TTLe-3 12.54 12.59 12.77 12.63 0.94 12.77 12.62 12.66 12.69 0.62 12.79 12.52 12.84 12.72 1.37 12.68 0.93 Deamidation (N30)

Three individual preparations of digested peptides were prepared and analyzed each day. a, Intra-assay CV (%); b, Inter-assay CV (%); c, Glycosylation; d, TTH and TTL are the peptides containing the CDR region of trastuzumab; e, TH and TL are the peptides containing the constant region of trastuzumab